Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 5.92% is 91% above its 5-year average of 3.10%, near the high end of its 5-year range (0.00%–8.09%).
As of the fiscal period ended Tuesday, June 30, 2026. 4.69% below its 12-month average of 6.21%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 5.92%.
DEBT TO ASSETS RATIO
5.92%
DEBT TO ASSETS RATIO AVG TTM
6.21%
DEBT TO ASSETS RATIO AVG 3Y
4.26%
DEBT TO ASSETS RATIO AVG 5Y
3.10%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-4.69%
CURRENT VS 3Y AVG
+38.98%
CURRENT VS 5Y AVG
+90.86%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 873 covered companies
CURRENT VS SECTOR MEDIAN
+6478.15%
vs the sector median at left
Cytek Biosciences, Inc.
Market Cap
$694.79M
Debt to Assets Ratio
5.92%
TTM Avg
6.21%
3Y Avg
4.26%
5Y Avg
3.10%
Market Cap
$693.61M
Debt to Assets Ratio
0.08%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$693.19M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$691.79M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$702.82M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$685.49M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$681.27M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$709.65M
Debt to Assets Ratio
0.40%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cytek Biosciences, Inc. (CTKB) | $694.79M | 5.92% | 6.21% | 4.26% | 3.10% |
| Wave Life Sciences Ltd. (WVE)vs › | $693.61M | 0.08% | N/A | N/A | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $693.19M | 0.00% | N/A | N/A | N/A |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $691.79M | 0.00% | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $702.82M | 0.00% | N/A | N/A | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $685.49M | 0.01% | N/A | N/A | N/A |
| Solid Biosciences Inc. (SLDB)vs › | $681.27M | 0.05% | N/A | N/A | N/A |
| Verastem, Inc. (VSTM)vs › | $681.02M | 0.41% | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.65M | 0.40% | N/A | N/A | N/A |
| Avalo Therapeutics, Inc. (AVTX)vs › | $714.37M | 0.00% | N/A | N/A | N/A |
Debt/Assets
5.9%
Debt/Equity
0.08
Current Ratio
4.48
Interest Coverage
-85.2x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 5.92% |
| 2026-03-31 | 8.09% |
| 2025-12-31 | 5.14% |
| 2025-09-30 | 7.10% |
| 2025-06-30 | 4.80% |
| 2025-03-31 | 3.29% |
| 2024-12-31 | 3.41% |
| 2024-09-30 | 2.96% |
| 2024-06-30 | 2.85% |
| 2024-03-31 | 2.92% |
| 2023-12-31 | 2.86% |
| 2023-09-30 | 2.95% |
| 2023-06-30 | 3.09% |
| 2023-03-31 | 3.29% |
| 2022-12-31 | 3.48% |
| 2022-09-30 | 3.15% |
| 2022-06-30 | 3.01% |
| 2022-03-31 | 3.07% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 1.24% |
| 2020-12-31 | 1.26% |
